跳至主要内容
临床试验/NL-OMON56968
NL-OMON56968尚未招募3 期

A clinical performance study for testing FFPE tissue samples, with therascreen® KRAS RGQ PCR kit, to determine KRAS G12C mutation for potential enrollment into clinical study BO45217 - Performance study: KRAS G12C mutation for enrollment into study BO45217

Roche Nederland B.V.0 个研究点目标入组 23 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
23

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Tissue inclusion / exclusion criteria: Tumor specimens will be formalin-fixed,
  • paraffin-embedded (FFPE) in a paraffin block (preferred) or 10-15 (15
  • preferred) unstained, freshly cut, serial slides and should be of good quality,
  • with a minimum of 500 viable tumor cells. Samples collected via resection, core
  • needle biopsy, excisional, incisional, punch, or forceps biopsy, or
  • endobronchial ultrasound (EBUS)-transbronchial needle aspiration are
  • acceptable. Samples that do not preserve tissue architecture, including
  • fine-needle aspiration, brushing, cell pellets from pleural effusion, and
  • lavage samples are not acceptable. Tumor tissue from bone metastases that have
  • been decalcified is not acceptable.
  • Details on the inclusion criteria of the study subjects are described in
  • Section 5.1 of the clinical trial protocol for BO45217

排除标准

  • Details on the exclusion criteria of the study subjects are described in
  • Section 5.1 of the clinical trial protocol for BO45217

研究者

相似试验